Research Article
Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Table 5
The presentation of percentage PANSS-derived responder rates (per-protocol set and intention-to-treat).
| PANSS | Total | <25% PANSS | 25–49% PANSS | 50–74% PANSS | 75–100% PANSS | Reduction (%) | Reduction (%) | Reduction (%) | Reduction (%) |
| PPS | | | | | | TJ-54 group | 48 | 28 (58.3) | 15 (31.3) | 4 (8.3) | 1 (2.1) | Placebo group | 50 | 40 (80.0) | 8 (16.0) | 2 (4.0) | 0 (0) | ITT | | | | | | TJ-54 group | 54 | 29 (53.7) | 18 (33.3) | 6 (11.1) | 1 (1.8) | Placebo group | 60 | 44 (73.3) | 12 (20.0) | 4 (6.7) | 0 (0) |
|
|
There was no statistical significant difference. PPS: per-protocol set; ITT: intention-to-treat.
|